Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Jun;36(4):428-34.
doi: 10.1016/j.jsat.2008.09.001. Epub 2008 Nov 11.

Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting

Abigail C Halperin  1 , Timothy A McAfee, Lisa M Jack, Sheryl L Catz, Jennifer B McClure, T Mona Deprey, Julie Richards, Susan M Zbikowski, Gary E Swan
Affiliations
Randomized Controlled Trial

Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting

Abigail C Halperin et al. J Subst Abuse Treat. 2009 Jun.

Abstract

This article examines reported symptoms, nonsmoking rates, and medication use among 1,018 smokers using varenicline in a randomized trial comparing three forms of behavioral support for smoking cessation (phone, Web, or phone + Web). One month after beginning varenicline, 168 people (17%) had discontinued the medication. Most (53%) quit due to side effects and other symptoms. The most common side effect among all users was nausea (reported by 57% of users). At 1 month post medication initiation, those not taking varenicline were more likely to report smoking than those who continued the medication (57% vs. 16%, p < .001). Women reported more symptoms but did not discontinue medication at higher rates. Participants who received any telephone counseling (n = 681) were less likely to discontinue their medication than those with Web support only (15% vs. 21%, p < .01). Counseling may improve tolerance of this medication and reduce the rate of discontinuation due to side effects.

Trial registration: ClinicalTrials.gov NCT00301145.

PubMed Disclaimer

References

    1. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Statistical Methodology) 1995;57:289–300.
    1. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR. Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs. Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial. JAMA: The Journal of the American Medical Association. 2006;296:47–55. - PubMed
    1. Hughes JR. Effects of abstinence from tobacco: Valid symptoms and time course. Nicotine & Tobacco Research. 2007;9:315–327. - PubMed
    1. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR. Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs. Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial. JAMA: The Journal of the American Medical Association. 2006;296:56–63. - PubMed
    1. Leabman MK, Huang CC, Stryke D, Johns SJ, Kawamoto M, Ferrin TE, DeYoung J, Taylor TR, De La Cruz M, Herskowitz I, Giacomini KM. PharmGKB Update: I. Genetic Variants of the Organic Cation Transporter 2 (OCT2, SLC22A2) Pharmacological Reviews. 2003;55:399. - PubMed

Publication types

MeSH terms

Associated data